Dr. Jiajia Huang 黄嘉佳
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of breast tumors, including chemotherapy, endocrine therapy, targeted immunotherapy, individualized treatment, and comprehensive management.
Dr. Huang is a Chief Physician and MD with a master’s supervisor role. Dr. Huang was a visiting scholar at the Institute of Oncology in Southern Switzerland and UC San Diego Moores Cancer Center. Dr. Huang leads projects funded by the National Natural Science Foundation and others, participates in international multicenter new drug trials, and has published SCI papers in journals such as Annals of Oncology.
Professional roles
- Vice Chair, Tumor Immunotherapy Professional Committee, China Health Care Association for the Elderly
- Standing Committee Member, Second Breast Cancer Professional Committee, Chinese Women Doctors Association
- Vice Chair, Breast Tumor Medical Management Branch, Guangdong Medical Industry Association
- Standing Committee Member, Youth Committee of Targeted and Individualized Therapy Professional Committee, Guangdong Anti-Cancer Association
Name order: in Chinese the family name comes first (Huang Jiajia). Papers usually list the name as Jiajia Huang or Huang J.
Selected publications
77 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2025 (first author): Real-world treatment patterns and outcomes among patients with HER2-positive unresectable or metastatic breast cancer in China. PubMed 40438675
- Biomark Med, 2023 (senior author): Pretreatment soluble Siglec-5 protein predicts early progression and R-CHOP efficacy in diffuse large B-cell lymphoma. PubMed 37097021
- Front Cell Dev Biol, 2022 (senior author): The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer. PubMed 35281097
- Int J Womens Health, 2021 (senior author): An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Breast Cancer. PubMed 34785957
- Front Oncol, 2020 (senior author): The Prognostic Prediction Value of Systemic Inflammation Score and the Development of a Nomogram for Patients With Surgically Treated Breast Cancer. PubMed 33194636
- Cancer Med, 2019 (senior author): Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma. PubMed 31218841
- Oncotarget, 2016 (first author): A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution. PubMed 27183909
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion